Journal article
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, J-J Grob, CL Cowey, CD Lao, J Wagstaff, D Schadendorf, PF Ferrucci, M Smylie, R Dummer, A Hill, D Hogg, J Haanen, MS Carlino, O Bechter, M Maio, I Marquez-Rodas, M Guidoboni Show all
NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2017
Abstract
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS: We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogr..
View full abstractGrants
Awarded by NATIONAL CANCER INSTITUTE
Funding Acknowledgements
Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.